IndustryCompany release

Harrow reports record $99.3M Q3 revenue but cuts 2026 Adjusted EBITDA outlook

🇺🇸 Harrow, Inc. (HROW) · Mon 09 Nov 2026

The US ophthalmic company held its full-year sales guidance, lowered its profit outlook to above $40 million, and brought forward its planned G-MELT NDA submission to 2026.

Harrow, Inc. reported record third-quarter 2026 revenue of $99.3 million in a stockholder letter dated 9 November 2026. The company attributed the result to its branded ophthalmic products, naming VEVYE, IHEEZO, TRIESENCE and BYOOVIZ.

Full-year revenue guidance was reaffirmed at $350 million to $365 million. Adjusted EBITDA guidance was reduced, however, from a range of $80 million to $100 million to more than $40 million. Harrow cited a gross-to-net shortfall for VEVYE in the first half of the year and accelerated spending on research and development.

On the pipeline, Harrow plans to submit a new drug application (NDA) to the US Food and Drug Administration for G-MELT during 2026. That is earlier than the first-half 2027 timing it had previously guided.

The company also expects a new VEVYE coverage win that would extend access to more than 10 million commercial lives from 1 January. The summary available does not identify the payer or give further detail on the terms.

What it means for your team

  • Market-access teams may note that a gross-to-net shortfall was cited as a material drag on VEVYE profitability, even with record company revenue.
  • A coverage win for over 10 million commercial lives from 1 January points to continued payer-driven shifts in ophthalmic product access.
  • Regulatory teams should watch for the G-MELT NDA, now planned for 2026 rather than the first half of 2027; the FDA's acceptance decision will follow after submission.

Company's press release (SEC filing): Harrow, Inc. ↗

Article written by VigiEye from the official source (Harrow, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →